miR-125a-3p在急性髓细胞白血病患者外周血中的表达及其意义*

doi:10.3969/j.issn.1671-2587.2016.02.012

临床输血与检验 ›› 2016, Vol. 18 ›› Issue (2): 127-130.DOI: 10.3969/j.issn.1671-2587.2016.02.012

miR-125a-3p在急性髓细胞白血病患者外周血中的表达及其意义*

潘请, 彭静, 孙晓曦, 戴春阳, 马筱玲

233030 安徽省蚌埠医学院（潘请）; 安徽医科大学附属省立医院检验科（潘请,彭静,孙晓曦,戴春阳,马筱玲）

收稿日期:2015-11-12 出版日期:2016-04-20 发布日期:2016-09-21
通讯作者: 马筱玲,（E-mail）xiaolingma@126.com。
作者简介:潘请（1985-）,女,山东菏泽人,检验技师,在读硕士研究生,主要从事细菌耐药性研究,（Tel）15555109193（E-mail）qingqingpan@126.com。
基金资助:
*本课题受安徽省自然科学基金（No.1408085MH188）资助

The Expression and Significance of MiR-125a-3p in Peripheral Blood of Patients with Acute Myeloid Leukemia

PAN Qing, PENG Jing, SUN Xiao-xi, DAI Chun-yang, MA Xiao-ling, et al

Bengbu Medical College,Bengbu,Anhui 233030

Received:2015-11-12 Online:2016-04-20 Published:2016-09-21

摘要/Abstract

摘要： 目的探讨miR-125a-3p在急性髓细胞白血病( Acute myeloid leukemia,AML）患者外周血中的表达及其意义。方法采用实时荧光定量PCR检测119例AML患者外周血标本中miR-125a-3p的表达水平,其中,初诊组53例,复发组12例,治疗组54例。另选择12例正常人作为对照。随机选择初诊组中7例患者进行外周血miR-125a-3p动态监测。结果与正常对照组比较,初诊组和复发组患者外周血miR-125a-3p的表达水平明显减低,且差异有统计学意义（P < 0.05）,而治疗组患者外周血miR-125a-3p的表达水平增高,但差异无统计学意义（P > 0.05）。对初诊组和治疗组中不同FAB分型的AML患者miR-125a-3p的表达水平进行比较,发现初诊组内各型患者之间miR-125a-3p表达的差异无统计学意义（P > 0.05）;治疗组内M4型AML患者miR-125a-3p表达明显高于M0 型,差异有统计学意义（P <0.05）,其他各型之间miR-125a-3p表达差异无统计学意义（P > 0.05）。7 例患者miR-125a-3p动态监测结果显示,在治疗过程中,miR-125a-3p表达一直维持在较高的水平;1例患者缓解4~5个疗程后复发,其miR-125a-3p表达再次降低。结论miR-125a-3p在AML 初发及复发患者外周血中低表达,诱导治疗后表达量升高,这可能与AML的发生发展有关,miR-125a-3p有望成为AML疗效评价和复发监测的生物学指标。

关键词: miR-125a-3p, 急性髓细胞白血病, 实时荧光定量PCR, 动态监测, 生物学指标

Abstract: ObjectiveThis study was to investigate the expression and significance of miR-125a-3p in peripheral blood of Acute myeloid leukemia patients. MethodsReal-time fluorescent quantitative PCR was performed to detect the expression levels of miR-125a-3p in peripheral blood specimens of 119 AML patients, including 53 newly diagnosed, 12 relapsed and 54 treated patients. In addition, 12 healthy persons were selected as normal controls. Moreover, 7 persons were selected randomly from newly diagnosed patients for dynamic monitoring of miR-125a-3p levels in peripheral blood. ResultsCompared with normal controls, the expression levels of miR-125a-3p were decreased significantly in newly diagnosed and relapsed patients (P<0.05). However, miR-125a-3p expression in treated patients were increased (P> 0.05). The researchers compared respectively the expression levels of miR-125a-3p in different FAB subtypes of newly diagnosed and treated patients and found that there were no significant differences among various subtypes in newly diagnosed patients (P>0.05). In treated patients, the expression of miR-125a-3p in M4 patients was significantly higher than it in M0 (P<0.05), however, the differences between other subtype patients were not significant (P>0.05). Dynamic monitoring of miR-125a-3p levels of 7 patients showed that miR-25a-3p expression maintained a higher level in the process of the treatment; when one patient with remission relapsed after 4~5 courses of treatment, miR-125a-3p expression reduced again. ConclusionThe expression of miR-125a-3p is obviously decreased in patients with newly diagnosed and relapsed AML, and chemotherapy arises the expression level, which may be related with the occurrence and development of AML. Thus miR-125a-3p is expected to become a biological marker of AMLin evaluating for therapy efficacy and monitoring.

Key words: miR-125a-3p, Acute, myeloid, leukemia, Real-time, fluorescence, quantitative, PCR, Dynamic, monitoring, Biological, marker

中图分类号:

R733.7R392.11

潘请, 彭静, 孙晓曦, 戴春阳, 马筱玲. miR-125a-3p在急性髓细胞白血病患者外周血中的表达及其意义*[J]. 临床输血与检验, 2016, 18(2): 127-130.

PAN Qing, PENG Jing, SUN Xiao-xi, DAI Chun-yang, MA Xiao-ling, et al. The Expression and Significance of MiR-125a-3p in Peripheral Blood of Patients with Acute Myeloid Leukemia[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2016, 18(2): 127-130.

参考文献

[1] Yuan Y, Kasar S, Underbayev C, et al. MicroRNAs in Acute Myeloid Leukemia and Other Blood Disorders[J]. Leuk Res Treatment, 2012, 2012: 603830.
[2] Sun YM, Lin KY, Chen YQ. Diverse functions of mir-125 family in different cell contexts[J]. J Hematol Oncol, 2013, 6: 6.
[3] Zhang X, Nie Y, Du Y, et al. MicroRNA-181a promotes gastric cancer by negatively regulating tumor suppressor KLF6[J]. Tumour Biol, 2012, 33(5): 1589-1597.
[4] Wu N, Lin X, Zhao X,et al. MiR-125b acts as an oncogene in glioblastoma cells and inhibits cell apoptosis through p53 and p38MAPK-independent pathways[J]. Br J Cancer, 2013 ,109(11): 2853-2863.
[5] Shi XB, Xue L, Ma AH, et al. Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells [J]. Oncogene, 2013, 32(35): 4130-4138.
[6] Jiang L, Chang J, Zhang Q, et al. MicroRNA hsa-miR-125a-3p activates p53 and induces apoptosis in lung cancer cells[J]. Cancer Invest, 2013, 31(8): 538-544.
[7] Huang B, Luo W, Sun L, et al. MiRNA-125a-3p is a negative regulator of the RhoA-actomyosin pathwayin A549 cells[J]. Int J Oncol, 2013, 42(15): 1734-1742.
[8] Jiang L, Huang Q, Zhang S, et al. Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells[J]. BMC Cancer, 2010, 10: 318.
[9] Zhang H, Zhu X, Li N, et al. miR-125a-3p targets MTA1 to suppress NSCLC cell proliferation, migration, and invasion[J]. Acta Biochim Biophys Sin (Shanghai), 2015, 47(7): 496-503.
[10] Yin F, Zhang JN, Wang SW,et al. MiR-125a-3p regulates glioma apoptosis and invasion by regulating Nrg1[J]. PLoS ONE, 2015, 10(1): e116759.
[11] Hashiguchi Y, Nishida N, Mimori K, et al. Down-regulation of miR-125a-3p in human gastric cancer and its clinicopathological significance[J]. Int J Oncol, 2012, 40(5): 1477-1482.
[12] Ninio-Many L, Grossman H, Levi M, et al. MicroRNA miR-125a-3p modulates molecular pathway of motility and migration in prostate cancer cells[J]. Oncoscience, 2014, 1(4): 250-261.
[13] Ninio-Many L, Grossman H, Shomron N, et al. microRNA-125a-3p reduces cell proliferation and migration by targeting Fyn[J]. J Cell Sci, 2013, 126 (Pt 13) : 2867-2876.
[14] 张之南, 沈悌. 血液病诊断及疗效标准[M]. 第3版.北京:科学出版社, 2007: 106-116.
[15] Liclican EL, Walser TC, Hazra S, et al. Loss of miR125a expression in a model of K-ras-dependent pulmonary premalignancy[J]. Cancer Prev Res (Phila), 2014, 7(8): 845-855.
[16] Ufkin ML, Peterson S, Yang X, et al. miR-125a regulates cell cycle, proliferation, and apoptosis by targeting the ErbB pathway in acute myeloid leukemia[J]. Leuk Res, 2014, 38(3): 402-410.

miR-125a-3p在急性髓细胞白血病患者外周血中的表达及其意义*

The Expression and Significance of MiR-125a-3p in Peripheral Blood of Patients with Acute Myeloid Leukemia

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 5

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	曾凡荣, 刘江, 杨光, 王小波, 张洁, 何玢, 朱利杰, 孙梦阳, 余寿杰. 淮南市新型冠状病毒感染病例实验室核酸检测结果分析[J]. 临床输血与检验, 2020, 22(4): 371-375.
[2]	沈季敏, 刘欣, 王兴兵. TLR-3激动剂联合TLR-9激动剂对树突状细胞细胞形态及免疫表型的影响*[J]. 临床输血与检验, 2020, 22(1): 71-76.
[3]	凡任芝. 血浆EB病毒DNA浓度检测在初诊鼻咽癌患者分期中的应用[J]. 临床输血与检验, 2017, 19(5): 462-465.
[4]	徐瑞琴, 胡可妮. 急性髓细胞白血病微小残留病灶经骨髓活检的应用价值[J]. 临床输血与检验, 2017, 19(1): 79-82.
[5]	姬长甫, 尹惠琼, 贾俊婷, 王蕊, 朱凤宣, 杨姝, 章金刚. 新型BCA中基于实时荧光定量PCR的条形码DNA定量方法的建立*[J]. 临床输血与检验, 2016, 18(3): 258-261.